These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31698973)

  • 1. Canagliflozin and Amputation Risk: Evidence So Far.
    Papadokostaki E; Rizos E; Tigas S; Liberopoulos EN
    Int J Low Extrem Wounds; 2020 Mar; 19(1):21-26. PubMed ID: 31698973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D).
    Ryan PB; Buse JB; Schuemie MJ; DeFalco F; Yuan Z; Stang PE; Berlin JA; Rosenthal N
    Diabetes Obes Metab; 2018 Nov; 20(11):2585-2597. PubMed ID: 29938883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence.
    Katsiki N; Dimitriadis G; Hahalis G; Papanas N; Tentolouris N; Triposkiadis F; Tsimihodimos V; Tsioufis C; Mikhailidis DP; Mantzoros C
    Metabolism; 2019 Jul; 96():92-100. PubMed ID: 30980838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
    Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions.
    Matharu K; Chana K; Ferro CJ; Jones AM
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00867. PubMed ID: 34586753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
    Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
    BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibitors and lower limb complications: an updated meta-analysis.
    Lin C; Zhu X; Cai X; Yang W; Lv F; Nie L; Ji L
    Cardiovasc Diabetol; 2021 Apr; 20(1):91. PubMed ID: 33910574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio.
    Kaneko M; Narukawa M
    Clin Drug Investig; 2019 Feb; 39(2):179-186. PubMed ID: 30506378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials.
    Li D; Yang JY; Wang T; Shen S; Tang H
    Diabetes Metab; 2018 Nov; 44(5):410-414. PubMed ID: 29506779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis.
    Heyward J; Mansour O; Olson L; Singh S; Alexander GC
    PLoS One; 2020; 15(6):e0234065. PubMed ID: 32502190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.
    Arnott C; Huang Y; Neuen BL; Di Tanna GL; Cannon CP; Oh R; Edwards R; Kavalam M; Rosenthal N; Perkovic V; Jardine MJ; Mahaffey K; Neal B
    Diabetes Obes Metab; 2020 Oct; 22(10):1753-1766. PubMed ID: 32436638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
    Täger T; Atar D; Agewall S; Katus HA; Grundtvig M; Cleland JGF; Clark AL; Fröhlich H; Frankenstein L
    Heart Fail Rev; 2021 Nov; 26(6):1421-1435. PubMed ID: 32314085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A safety update on sodium glucose co-transporter 2 inhibitors.
    Fitchett D
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():34-42. PubMed ID: 31081590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of five randomized controlled trials.
    Miyashita S; Kuno T; Takagi H; Sugiyama T; Ando T; Valentin N; Shimada YJ; Kodaira M; Numasawa Y; Kanei Y; Bangalore S
    Diabetes Res Clin Pract; 2020 May; 163():108136. PubMed ID: 32272190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we go beyond surrogates?
    Drexler A
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?
    Tanaka A; Node K
    Cardiovasc Diabetol; 2017 Oct; 16(1):129. PubMed ID: 29025400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?
    Khouri C; Cracowski JL; Roustit M
    Diabetes Obes Metab; 2018 Jun; 20(6):1531-1534. PubMed ID: 29430814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos.
    Huttunen R; Sainio A; Hjelt A; Haapanen-Saaristo AM; Määttä J; Rummukainen P; Paatero I; Järveläinen H
    Biomed Pharmacother; 2022 Dec; 156():113882. PubMed ID: 36265308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
    Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
    Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk of Amputation: What Is Currently Known?
    Misher A; Ampuero A; Phan R; Aziz S; Ebong E; Braich J; Dyches K; Southwood R
    Am J Ther; 2020 Mar; 28(1):e96-e110. PubMed ID: 32384319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.